Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bacterial DNA gyrase

2

Topoisomerase IV subunit A

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Infective ophthalmitis

2

Respiratory tract infections

2

Skin infections

2

Urinary tract infections

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Chugai Pharmaceutical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

FDA UNII

2

PUBCHEM

2

ChEMBL

1

DRUG CENTRAL

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

BALOFLOXACIN

Q022B63JPM

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Topoisomerase IV subunit A

Bacterial DNA gyrase

Conditions:

Urinary tract infections

Respiratory tract infections

Skin infections

Infective ophthalmitis

Balofloxacin (Q-35), is an orally active fluoroquinolone antibiotic. It has been developed for the treatment of urinary tract infection. The bactericidal action of Balofloxacin results from interference with the enqyme DNA gyrase which is needed for ...

the synthesis of bacterial DNA. Balofloxacin is efficacious against Gram-negative bacteria. It also has enhanced activity against Gram positive bacteria, including MRSA and Streptococcus pneumoniae. Side effects of Balofloxacin are: sensitivity to light, abdominal pain, nausea, heartburn, urticarial, irritation when applied locally. Balofloxacin may interact with the following medicines and salts: antacids, non-steroidal anti-inflammatory drug, quinolones, theophylline.

BALOFLOXACIN DIHYDRATE

SH1AVB6TVK

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Topoisomerase IV subunit A

Bacterial DNA gyrase

Conditions:

Urinary tract infections

Respiratory tract infections

Skin infections

Infective ophthalmitis

Balofloxacin (Q-35), is an orally active fluoroquinolone antibiotic. It has been developed for the treatment of urinary tract infection. The bactericidal action of Balofloxacin results from interference with the enqyme DNA gyrase which is needed for ...

the synthesis of bacterial DNA. Balofloxacin is efficacious against Gram-negative bacteria. It also has enhanced activity against Gram positive bacteria, including MRSA and Streptococcus pneumoniae. Side effects of Balofloxacin are: sensitivity to light, abdominal pain, nausea, heartburn, urticarial, irritation when applied locally. Balofloxacin may interact with the following medicines and salts: antacids, non-steroidal anti-inflammatory drug, quinolones, theophylline.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1